AMRI closes Cedarburg deal, sees adding 6c-7c to FY14 adjusted EPS AMRI announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals. Total consideration paid was $41M, including assumption of certain liabilities. AMRI financed the transaction with cash on hand. The acquisition is expected to add between $13M-$14M to AMRI's revenue in FY14. AMRI anticipates full year run-rate synergies of approximately $1.5M of EBITDA within 12 months of closing and the acquisition is expected to be accretive to AMRI's FY14 adjusted diluted EPS in the range of 6c-7c per share.